Sarilumab
- Generic Name
- Sarilumab
- Brand Names
- Kevzara
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1189541-98-7
- Unique Ingredient Identifier
- NU90V55F8I
- Background
Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approva...
- Indication
Sarilumab is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs); and adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tole...
- Associated Conditions
- Polymyalgia Rheumatica (PMR), Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
- Conditions
- Interventions
- Drug: Squaric Acid Dibutyl EsterOther: Known patch test allergensDevice: MicroneedleDrug: DupilumabDevice: Suction blisteringDrug: AdalimumabProcedure: Skin punch biopsyDrug: UstekinumabDrug: GuselkumabDrug: CanakinumabDrug: SarilumabDrug: Triamcinolone AcetonideDrug: Betamethasone ValerateDrug: Fluticasone Propionate
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- John Harris
- Target Recruit Count
- 45
- Registration Number
- NCT05535738
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 69
- Registration Number
- NCT05428007
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸The Angeles Clinic at Cedars Sinai, Los Angeles, California, United States
🇺🇸NYU Langone Health, New York, New York, United States
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 370
- Registration Number
- NCT05125016
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- University of Southern Denmark
- Target Recruit Count
- 3
- Registration Number
- NCT04842981
- Locations
- 🇩🇰
Odense University Hospital, Odense, Region Of Southern Denmark, Denmark
🇩🇰Danish Hospital for Rheumatic Diseases, Sønderborg, Region Of Southern Denmark, Denmark
🇩🇰Hospital South West Jutland, Esbjerg, Region Of Southern Denmark, Denmark
Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2020-12-16
- Target Recruit Count
- 60
- Registration Number
- NCT04661527
- Locations
- 🇪🇸
ClÃnica Universidad de Navarra, Universidad de Navarra, Pamplona, Navarra, Spain
🇪🇸Hospital Universitario Infanta Leonor, Madrid, Spain
A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 612
- Registration Number
- NCT04590326
- Locations
- 🇪🇸
Ciudad Universitaria, Madrid, Spain
🇪🇸Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM, Madrid, Spain
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Maria del Rosario Garcia de Vicuña Pinedo
- Target Recruit Count
- 30
- Registration Number
- NCT04357808
- Locations
- 🇪🇸
Hospital Universitario de la Princesa, Madrid, Spain
Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO
- Conditions
- Interventions
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2020-05-06
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 27
- Registration Number
- NCT04341870
- Locations
- 🇫🇷
AP-HP Hôpital Beaujon, Clichy, France
🇫🇷AP-HP Hôpital Pitié Salpétrière, Paris, France
🇫🇷AP-HP Hôpital Avicenne, Bobigny, France
Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 239
- Registration Number
- NCT04324073
- Locations
- 🇫🇷
Kremlin Bicetre hospital APHP, Le Kremlin-Bicêtre, Ile De France, France
🇫🇷NECKER Hospital, Paris, France
🇫🇷Cochin Aphp, Paris, Ile De France, France
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1912
- Registration Number
- NCT04315298
- Locations
- 🇺🇸
Regeneron Study Site, Renton, Washington, United States
🇺🇸Regeneron Study Site 1, New York, New York, United States
🇺🇸Regeneron Study Site 2, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.